- Home
- MRNO vs CSTL Comparison
MRNO vs CSTL Comparison
Compare MRNO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNO
- CSTL
- Stock Information
- Founded
- MRNO 2021
- CSTL 2007
- Country
- MRNO United Kingdom
- CSTL United States
- Employees
- MRNO N/A
- CSTL N/A
- Industry
- MRNO
- CSTL Medical Specialities
- Sector
- MRNO
- CSTL Health Care
- Exchange
- MRNO NYSE
- CSTL Nasdaq
- Market Cap
- MRNO 794.8M
- CSTL 848.1M
- IPO Year
- MRNO N/A
- CSTL 2019
- Fundamental
- Price
- MRNO $9.52
- CSTL $27.39
- Analyst Decision
- MRNO
- CSTL Strong Buy
- Analyst Count
- MRNO 0
- CSTL 7
- Target Price
- MRNO N/A
- CSTL $37.57
- AVG Volume (30 Days)
- MRNO 4.5K
- CSTL 315.1K
- Earning Date
- MRNO 12-31-2024
- CSTL 11-04-2024
- Dividend Yield
- MRNO N/A
- CSTL N/A
- EPS Growth
- MRNO N/A
- CSTL N/A
- EPS
- MRNO N/A
- CSTL 0.21
- Revenue
- MRNO $24,458,160.00
- CSTL $311,878,000.00
- Revenue This Year
- MRNO N/A
- CSTL $51.36
- Revenue Next Year
- MRNO N/A
- CSTL N/A
- P/E Ratio
- MRNO N/A
- CSTL $135.05
- Revenue Growth
- MRNO 296.23
- CSTL 62.43
- 52 Week Low
- MRNO $3.60
- CSTL $16.97
- 52 Week High
- MRNO $38.00
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- MRNO 45.02
- CSTL 39.09
- Support Level
- MRNO $9.53
- CSTL $27.51
- Resistance Level
- MRNO $11.51
- CSTL $32.57
- Average True Range (ATR)
- MRNO 0.96
- CSTL 1.55
- MACD
- MRNO -0.17
- CSTL -0.23
- Stochastic Oscillator
- MRNO 0.00
- CSTL 17.49
About MRNO MURANO GLOBAL INVESTMENTS LIMITED
Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to our customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.